Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
State-of-the-Art Role of the Tumor Microenvironment in Cancer Progression and...
share announcement

State-of-the-Art Role of the Tumor Microenvironment in Cancer Progression and Treatment in France

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 5140

Special Issue Editors

Dr. Jerome Devy

E-Mail Website
Guest Editor
Matrice Extracellulaire et Dynamique Cellulaire, MEDyC, UMR 7369 CNRS-URCA, Université de Reims Champagne-Ardenne, 51687 Reims CEDEX 2, France
Interests: breast cancer; extracellular matrix; metastasis; cell adhesion; ECM receptors; proteolysis; angiogenesis; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals
Dr. Stephane Potteaux

E-Mail Website
Guest Editor
Paris Cardiovascular Research Center (PARCC), Université René Descartes Paris 5, Paris, France
Interests: breast cancer

Special Issue Information

Dear Colleagues,

This Special Issue focuses on the “State-of-the-Art Role of the Tumor Microenvironment in Cancer Progression and Treatment in France”. Drug discovery and therapeutic opportunities in cancer treatment are very dynamic in France. Prediction of cancer evolution and sensitivity to treatments rapidly evolve thanks to a better comprehension of the tumorigenic processes and thanks to the establishment of transversal research. In an era where alternative methods (3R rule) to animal experimentation are encouraged, innovativeness is required to maintain research dynamism.

Original research articles and reviews, as well as manuscript dealing with methodological advances will be welcomed. We invite authors to contribute to this Special Issue of Biomedicines on topics related to:

  • Molecular mechanisms of cancer progression and therapeutic opportunities;
  • Epigenetic modulations of immune and stromal cells (microRNA, methylation/acetylation);
  • COVID-19 and cancer—an aggravating disease for cancer evolution;
  • Deciphering myeloid cell origins and roles in tumor development (macrophages and MDSC, where they come from and what their functions are);
  • Immunotherapy and precision medicine (new approaches);
  • Crosstalk between cellular metabolism and immunotherapy (distinguishing molecular subtypes of cancers that may predict immunotherapy efficacy);
  • Tumor microenvironment associated with resistance to immunotherapies;
  • What is new in imaging/theranostics;
  • Dynamics in and out of tumors (imaging of cell–cell interaction and metastasis formation);
  • Alternative methods of experimentation (reduce, refine, replace);
  • Prediction of immunotherapy efficacy in cancer (Immunoscore, ICI, imaging, machine learning, genetics);
  • In vitro 3D (organoids, tumoroids) models to recapitulate the tumor microenvironment (toward the end of animal experimentation).

Dr. Jerome Devy
Dr. Stephane Potteaux
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

19 pages, 354 KiB  
Review
Narrative Review of Synergistics Effects of Combining Immunotherapy and Stereotactic Radiation Therapy
by François Lucia, Margaux Geier, Ulrike Schick and Vincent Bourbonne
Biomedicines 2022, 10(6), 1414; https://doi.org/10.3390/biomedicines10061414 - 15 Jun 2022
Cited by 6 | Viewed by 1599
Abstract
Stereotactic radiotherapy (SRT) has become an attractive treatment modality in full bloom in recent years by presenting itself as a safe, noninvasive alternative to surgery to control primary or secondary malignancies. Although the focus has been on local tumor control as the therapeutic [...] Read more.
Stereotactic radiotherapy (SRT) has become an attractive treatment modality in full bloom in recent years by presenting itself as a safe, noninvasive alternative to surgery to control primary or secondary malignancies. Although the focus has been on local tumor control as the therapeutic goal of stereotactic radiotherapy, rare but intriguing observations of abscopal (or out-of-field) effects have highlighted the exciting possibility of activating antitumor immunity using high-dose radiation. Furthermore, immunotherapy has revolutionized the treatment of several types of cancers in recent years. However, resistance to immunotherapy often develops. These observations have led researchers to combine immunotherapy with SRT in an attempt to improve outcomes. The benefits of this combination would come from the stimulation and suppression of various immune pathways. Thus, in this review, we will first discuss the immunomodulation induced by SRT with the promising results of preclinical studies on the changes in the immune balance observed after SRT. Then, we will discuss the opportunities and risks of the combination of SRT and immunotherapy with the preclinical and clinical data available in the literature. Furthermore, we will see that many perspectives are conceivable to potentiate the synergistic effects of this combination with the need for prospective studies to confirm the encouraging data. Full article
(This article belongs to the Special Issue State-of-the-Art Role of the Tumor Microenvironment in Cancer Progression and Treatment in France)
17 pages, 1416 KiB  
Review
Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review
by Vincent Bourbonne, Margaux Geier, Ulrike Schick and François Lucia
Biomedicines 2022, 10(6), 1237; https://doi.org/10.3390/biomedicines10061237 - 26 May 2022
Cited by 6 | Viewed by 2994
Abstract
Immune checkpoint inhibitors (ICI) have revolutionized the management of locally advanced and advanced non-small lung cancer (NSCLC). With an improvement in the overall survival (OS) as both first- and second-line treatments, ICIs, and especially programmed-death 1 (PD-1) and programmed-death ligands 1 (PD-L1), changed [...] Read more.
Immune checkpoint inhibitors (ICI) have revolutionized the management of locally advanced and advanced non-small lung cancer (NSCLC). With an improvement in the overall survival (OS) as both first- and second-line treatments, ICIs, and especially programmed-death 1 (PD-1) and programmed-death ligands 1 (PD-L1), changed the landscape of thoracic oncology. The PD-L1 level of expression is commonly accepted as the most used biomarker, with both prognostic and predictive values. However, even in a low expression level of PD-L1, response rates remain significant while a significant number of patients will experience hyperprogression or adverse events. The dentification of such subtypes is thus of paramount importance. While several studies focused mainly on the prediction of the PD-L1 expression status, others aimed directly at the development of prediction/prognostic models. The response to ICIs depends on a complex physiopathological cascade, intricating multiple mechanisms from the molecular to the macroscopic level. With the high-throughput extraction of features, omics approaches aim for the most comprehensive assessment of each patient. In this article, we will review the place of the different biomarkers (clinical, biological, genomics, transcriptomics, proteomics and radiomics), their clinical implementation and discuss the most recent trends projecting on the future steps in prediction modeling in NSCLC patients treated with ICI. Full article
(This article belongs to the Special Issue State-of-the-Art Role of the Tumor Microenvironment in Cancer Progression and Treatment in France)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop